Drug Approval | June 12, 2024
Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release capsules
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Subscribe To Our Newsletter & Stay Updated
